Немецкий медицинский журнал Немецкий медицинский журнал

Coronary Stents
THE JOURNAL OF MEDICINE FOR THE WORLDWIDE MED COMMUNITY
Коронарные стенты
Literature
1. Stone GW, Moses JW, Ellis SG, et al
(2007) Safety and efficacy of sirolimusand
paclitaxel-eluting coronary stents.
N Engl J Med 356: 998-1008.
2. Stettler C, Wandel S, Allemann S, et
al (2007) Outcomes associated with
drug-eluting and bare-metal stents: a
collaborative network meta-analysis.
Lancet 370: 937-948
3. Nienaber CA, Akin I, Schneider S,
et al (2009) Clinical outcomes after
sirolimus-eluting, paclitaxel-eluting and
bare-metal stents (from the first phase
of the prospective multicenter German
DES.DE registry. Am J Cardiol 104:
1362-1369.
4. Pfisterer M, Brunner-La Rocca HP,
Buser PT, et al (2006) Late clinical
events after clopidogrel discontinuation
may limit the benefit of drug-eluting
stents: an observational study of drugeluting
versus bare-metal stents. J Am
Coll Cardiol 48: 2584-2591.
5. Lagerqvist B, James SK, Stenestrand
U, et al (2007) Long-term outcomes
with drug-eluting stents versus baremetal
stents in Sweden. N Engl J Med
356: 1009-1019.
6. Kirtane AJ, Gupta A, Iyengar S, et al
(2009) Safety and efficacy of drug-eluting
and bare metal stents: comprehensive
meta-analysis of randomized trials
and observational studies. Circulation
119: 3198-3206.
7. Mauri L, Hsieh WH, Massaro JM, et al
(2007) Stent thrombosis in randomized
clinical trials of drug-eluting stents. N
Engl J Med 356: 1020-1029.
8. Finn AV, Kolodgie FD, Harnek J, et al
(2005) Differential response of delayed
healing and persistent inflammation
at sites of overlapping sirolimus- or
paclitaxel-eluting stents. Circulation
2005; 112:270-278.
9. Virmani R, Guagliumi G, Farb A, et al
(2004). Localized hypersensitivity and
late coronary thrombosis secondary to
a sirolimus-eluting stent: should we be
cautious Circulation 109: 701-705.
10. Iakovou I, Schmidt T, Bonizzoni E, et
al (2005) Incidence, predictors, and
outcome of thrombosis after successful
implantation of drug-eluting stents.
JAMA 293: 2126-2130.
11. Daemen J, Wenaweser P, Tsuchida
K, et al (2007) Early and late coronary
stent thrombosis of sirolimus-eluting
and paclitaxel-eluting stents in routine
clinical practice: data from a large twoinstitutional
cohort study. Lancet 369:
667-678.
12. Wenaweser P, Daemen J, Zwahlen M,
et al (2008) Incidence and correlates
of drug-eluting stent thrombosis in
routine clinical practice. 4-year results
from a large 2-institutional cohort
study.J Am Coll Cardiol 52: 1134-1140.
13. Garg P, Cohen DJ, Gaziano T, Mauri L
(2008) Balancing the risks of restenosis
and stent thrombosis in bare-metal
versus drug-eluting stents: results of
a decision analytic model. J Am Coll
Cardiol 51: 1844-1853.
14. Stone GW, Ellis SG, Colombo A, et al
(2007) Offsetting impact of thrombosis
and restenosis on the occurrence of
death and myocardial infarction after
paclitaxel-eluting and bare metal stent
implantation. Circulation 115: 2842-
2847.
15. Virmani R, Liistro F, Stankovic G, et
al (2002) Mechanism of late in-stent
restenosis after implantation of a paclitaxel
derivate-eluting polymer stent
system in humans. Circulation 106:
2649-2651.
16. Joner M, Finn AV, Farb A, et al (2006)
Pathology of drug-eluting stents in
humans: delayed healing and late
thrombotic risk. J Am Coll Cardiol
48:193-202.
17. Kastrati A, Mehilli J, Dirschinger J, et al
(2001) Intracoronary stenting and angiographic
results: strut thickness effect
on restenosis outcome (ISAR-STEREO)
trial. Circulation 103: 2816-2821.
18. Popma JJ, Mauri L, O`Shaughnessy C,
et al (2009) Frequency and clinical consequences
associated with sidebranch
occlusion during stent implantation using
zotarolimus-eluting and paclitaxeleluting
coronary stents.Circ Cardiovasc
Interv 2: 133-139.
19. Meredith IT, Ormiston J, Whitbourn R,
et al (2005) First-in-human study of the
Endeavor ABT-578-eluting phosphorylcholine-encapsulated
stent system in
de novo native coronary artery lesions:
Endeavor I Trial. EuroIntervention 1:
157-164.
20. Awata M, Nanto S, Uematsu M, et
al (2008) Angioscopic comparison of
neointimal coverage between zotarolimus-
and sirolimus-eluting stents. J
Am Coll Cardiol 52:789-790.
21. Guagliumi G, Sirbu V, Musumeci G,
et al (2010) Strut coverage and vessel
wall response to a new-generation
paclitaxel-eluting stent with an ultrathin
biodegradable abluminal polymer:
Optical Coherence Tomography Drug-
Eluting STent Investigation (OCTDESI).
Circ Cardiovasc Interv 3: 367-375.
22. Fajadet J, Wijns W, Laarman GJ,
et al (2006) domized, double-blind,
multicenter study of the Endeavor
zotarolimus-eluting phosphorylcholineencapsulated
stent for treatment of native
coronary artery lesions: clinical and
angiographic results of the ENDEAVOR
II trial. Circulation 114: 798-806.
23. Kandzari DE, Leon MB, Popma JJ, et
al (2006) Comparison of zotarolimuseluting
and sirolimus-eluting stents in
patients with native coronary artery
disease: a randomized controlled trial.
J Am Coll Cardiol 48: 2440-2447.
24. Leon MB, Mauri L, Popma JJ, et al
(2010) A randomized comparison of
the ENDEAVOR zotarolimus-eluting
stent versus the TAXUS paclitaxel-eluting
stent in de novo native coronary
lesions 12-month outcomes from the
ENDEAVOR IV trial. J Am Coll Cardiol
55: 543-554.
25. Rasmussen K, Maeng M, Kaltoft A,
et al (2010) Efficacy and safety of
zotarolimus-eluting and sirolimus-eluting
coronary stents in routine clinical
care (SORT-OUT III): a randomised
controlled superiority trial. Lancet 375:
1090-1099.
26. Lotan C, Meredith IT, Liu M, et al
(2009) Safety and effectiveness of the
Endeavor zotarolimus-eluting stent in
real-world clinical practice: 12-month
data from the E-Five Registry. J Am
Coll Cardiol Interv 2: 1227-1235.
27. Camenzind E, Wijns W, Mauri L, et
al (2009) Rationale and design of
the Patient Related OuTcomes with
Endeavor versus Cypher stenting Trial
(PROTECT): randomized controlled
trial comparing the incidence of stent
thrombosis and clinical events after
sirolimus or zotarolimus drug-eluting
stent implantation. Am Heart J 158:
902-909.
28. Serruys PW, Ong AT, Piek JJ, et al
(2005) A randomized comparison of
a durable polymer Everolimus-eluting
stent with a bare metal coronary stent:
Dr. I. Akin (MD)
PD Dr. H. Schneider (MD)
Dr. S. Kische (MD)
PD Dr. T.C. Rehders (MD)
Dr. G.R. Turan (MD)
Prof. Dr. H. Ince (MD)
Prof. Dr. C.A. Nienaber (MD)
The SPIRIT first trial. EuroIntervention
1: 58-65.
29. Joner M, Nakazawa G, Finn AV, et
al (2008) Endothelial cell recovery
between comparator polymer-based
drug-eluting stents. J Am Coll Cardiol
52: 333-342.
30. Wiemer M, Serruys PW, Miquel-Hebert
K, et al (2010) Five-year long-term
clinical follow-up of the XIENCE V
everolimus eluting coronary stent system
in the treatment of patients with
de novo coronary artery lesions: the
SPIRIT FIRST trial. Catheter Cardiovasc
Interv 75: 997-1003.
31. Garg S, Serruys PW, Onuma Y, et al
(2009) 3-year clinical follow-up of the
XIENCE V everolimus-eluting coronary
stent system in the treatment of
patients with de novo coronary artery
lesions: the SPIRIT II trial (Clinical
Evaluation of the Xience V Everolimus
Eluting Coronary STent System in the
Treatment of Patients with de novo
Native Coronary Artery Lesions). JACC
Cardiovasc Interv 2: 1190-1198.
32. Stone GW, Midei M, Newman W, et al
(2008) Comparison of an everolimuseluting
stent and a paclitaxel-eluting
stent in patients with coronary artery
disease: a randomized trial. JAMA 299:
1903-1913.
33. Kedhi E, Joesoef KS, McFadden E, et
al (2010) Second-generation everolimus-eluting
and paclitaxel-eluting
stents in real-life practice (COMPARE):
a randomised trial. Lancet 375: 201-
209.
34. Nienaber CA (2010) Everolimus or
paclitaxel-eluting stent: go COMPARE.
Lancet 375; 174-176.
35. Claessen BE, Beijk MA, Legrand V, et
al (2009) Two-year clinical, angiographic,
and intravascular ultrasound followup
of the XIENCE V everolimus-eluting
stent in the treatment of patients with
de novo native coronary artery lesions:
the SPIRIT II trial. Circ Cardiovasc
Interv 2: 339-347.
36. Stone GW, Rizvi A, Newman W, et
al (2010) Everolimus-eluting versus
paclitaxel-eluting stents in coronary
artery disease. N Engl J Med 362:
1663-1674.
37. Lansky AJ, Applegate R, Hermiller JB,
et al (2009) Side-branch occlusion with
Xience V everolimus-eluting and Taxus
Express2 paclitaxel-eluting stents:
two-year results from the SPIRIT III
randomized trial. Am J Cardiol 104:
Suppl 6A:135D.
38. de la Torre Hernández JM, Alfonso F,
Gimeno F, et al (2010) Thrombosis of
second-generation drug-eluting stents
in real practice results from the multicenter
Spanish registry ESTROFA-2
(Estudio Espanol SObre Trombosis de
Stents Farmacoactivos de Segunda
Generacion-2). JACC Cardiovasc Interv
3: 911-919.
39. Serruys PW, Silber S, Garg S, et al
(2010) Comparison of zotarolimuseluting
and everolimus-eluting coronary
stents. N Engl J Med 363: 136-146.
40. Meredith IT, Worthley S, Whitbourn
R, et al (2007) The next-generation
Heart Center Rostock
Dept. of Internal Medicine I
University Hospital Rostock
Christoph.Nienaber@med.uni-rostock.de
Endeavor Resolute stent: 4-month
clinical and angiographic results from
the Endeavor Resolute first-in-man
trial. EuroIntervention 3: 50-53.
41. Windecker S, Serruys PW, Wandel
S, et al (2008) Biolimus-eluting stent
with biodegradable polymer versus
sirolimus-eluting stent with durable
polymer for coronary revascularisation
(LEADERS): a randomised non-inferiority
trial. Lancet 372: 1163-1173.
42. Barlis P, Regar E, Serruys PW, et al
(2010) An optical coherence tomography
study of a biodegradable vs.
durable polymer-coated limus-eluting
stent: a LEADERS trial sub-study. Eur
Heart J 31: 165-176.
43. Mehilli J, Kastrati A, Wessely R, et al
(2006) Randomized trial of a nonpolymer-based
rapamycin-eluting stent
versus a polymer-based paclitaxeleluting
stent for the reduction of late
lumen loss. Circulation 113: 273-279.
44. Ruef J, Störger H, Schwarz F, Haase J
(2008) Comparison of a polymer-free
rapamycin-eluting stent (YUKON) with
a polymer-based paclitaxel-eluting
stent (TAXUS) in real-world coronary
artery lesions.Catheter Cardiovasc
Interv 71: 333-339.
45. Ormiston JA, Serruys PW, Regar E, et
al (2008) A bioabsorbable everolimuseluting
coronary stent system for
patients with single de-novo coronary
artery lesions (ABSORB): a prospective
open-label trial. Lancet 371: 899-907.
46. Onuma Y, Serruys PW, Ormiston
JA, et al (2010) Three-year results of
clinical follow-up after a bioresorbable
everolimus-eluting scaffold in patients
with de novo coronary artery disease:
the ABSORB trial. EuroIntervention 6:
447-453.
47. Erbel R, Di Mario C, Bartunek J, et
al (2007) Temporary scaffolding of
coronary arteries with bioabsorbable
magnesium stents: a prospective, nonrandomised
multicentre trial. Lancet
369: 1869-1875.
39